Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;8(36):32222-32230.
doi: 10.1021/acsomega.3c05177. eCollection 2023 Sep 12.

Robert Letsinger and the Evolution of Oligonucleotide Synthesis

Affiliations

Robert Letsinger and the Evolution of Oligonucleotide Synthesis

Martin Egli. ACS Omega. .

Abstract

This retrospective summarizes a presentation given at the symposium "Bob Letsinger, PhD-100 Years of History" on September 28, 2021 as part of the 17th annual meeting of the Oligonucleotide Therapeutics Society (OTS). In it I look back at my encounters with Robert Lewis Letsinger (1921-2014) while at Northwestern University as Assistant Professor between 1995 and 2000.

PubMed Disclaimer

Conflict of interest statement

The author declares no competing financial interest.

Figures

Figure 1
Figure 1
Zoom picture of symposium speakers. Top row: Muthiah Manoharan (Alnylam Pharmaceuticals), Martin Egli (Vanderbilt University), Masad J. Damha (McGill University). Middle row: Marvin H. Caruthers (University of Colorado), Paul S. Miller (Johns Hopkins University), Margaret E. Schott (Northwestern University). Bottom row: Sergei M. Gryaznov (MAIA Biotechnology), Reed Letsinger (son). Missing: Chad A. Mirkin (NWU) and Kevin K. Ogilvie (former President of Acadia University and Senator for Annapolis Valley—Hants, Nova Scotia, Canada). Photo credit: Martin Egli.
Figure 2
Figure 2
Key steps in the development of oligonucleotide synthesis with selected contributions by Bob circled in red and a (very) brief history of chemically modified nucleic acids and the FDA approval of oligonucleotide therapeutics. See also: https://www.trilinkbiotech.com/a-short-history-of-oligonucleotide-synthesis. Adapted with permission from Egli, M.; Manoharan, M. Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics. Nucleic Acids Res. 2023, 51, 2529–2573. Copyright 2023 Oxford University Press.
Figure 3
Figure 3
Classification of synthetic oligonucleotides.
Figure 4
Figure 4
Key issues in the discovery and development of nucleic acid therapeutics.
Figure 5
Figure 5
Structures of (a) homo-DNA and (b) DNA and base pairing priorities in the two systems.
Figure 6
Figure 6
Conformational analysis of homo-DNA and the proposed (a) sc/sc and (b) ap/sc (α/ζ) backbone models. For the crystal structure of homo-DNA, please see ref (9).
Figure 7
Figure 7
Publication by Gryaznov and Letsinger in Nucleic Acids Research describing the synthesis and properties of oligonucleotides containing aminodeoxythymidine units. Adapted with permission from Gryzanov, S. M.; Letsinger, R. L. Synthesis and Properties of Oligonucleotides Containing Aminodeoxythymidine Units. Nucleic Acids Res. 1992, 20, 3403–3409. Copyright 1992 Oxford University Press.
Figure 8
Figure 8
Thermal stabilities of dodecamer duplexes with (a) DNA, (b) N3′ → P5′ phosphoramidate DNA, (c) P3′ → N5′ phosphoramidate DNA, and (d) RNA backbones. The Tm values were measured in 10 mM Tris·HCl pH 7.0 and 150 mM NaCl.
Figure 9
Figure 9
Ion coordination in the crystal structure of the N3′ → P5′ duplex [d(CnpGnpCnpGnpAnpAnpTnpTnpCnpGnpCnpG)]2 established the orientations of the 3′-amino group lone pair and hydrogen. Adapted with permission from Egli, M; Gryaznov, S. M. Synthetic Oligonucleotides as RNA Mimetics: 2′-Modified RNAs and N3′ → P5′ Phosphoramidates. Cell. Mol. Life Sci. 2000, 57, 1440–1456. Copyright 2000 Springer Nature.
Figure 10
Figure 10
Crystal structure of (a) N3′ → P5′ phosphoramidate-DNA helped rationalize its stable self-pairing and cross-pairing with and mimicking of RNA as well as the inability of (b) P3′ → N5′ phosphoramidate-DNA to self-pair and cross-pair with RNA. Nitrogen lone pair and P–O5′ antibonding orbital are indicated by green and black lobes, respectively, and a red arrow indicates a steric conflict. Adapted with permission from Tereshko, V.; Gryaznov, S.; Egli, M. Consequences of Replacing the DNA 3′-Oxygen by an Amino Group: High-Resolution Crystal Structure of a Fully Modified N3′ → P5′ Phosphoramidate DNA Dodecamer Duplex. J. Am. Chem. Soc. 1998, 120, 269–283. Copyright 1998 American Chemical Society.
Figure 11
Figure 11
Origins of AP-RNA’s resistance to degradation by SVPD. (a) Gel images depicting time courses (in min) of the degradation of DNA, PS-DNA and AP-RNA. (b) Crystal structure of the complex between E. coli DNA Pol I Klenow 3′-exonuclease and an oligo-2′-deoxynucleotide carrying three AP-RNA residues at its 3′-terminal end.
Figure 12
Figure 12
Mechanism of 3′-exonuclease inhibition by AP-RNA. The absence of a second metal ion due to formation of a salt bridge between Asp424 and the 2′-O-AP substituent prevents cleavage of the phosphodiester bond (red cross). Adapted with permission from Egli, M; Gryaznov, S. M. Synthetic Oligonucleotides as RNA Mimetics: 2′-Modified RNAs and N3′ → P5′ Phosphoramidates. Cell. Mol. Life Sci. 2000, 57, 1440–1456. Copyright 2000 Springer Nature.
Figure 13
Figure 13
Stilbene–diamide conjugation: electron transfer and record thermal stability.
Figure 14
Figure 14
Stereo diagram depicting face-to-face and edge-to-face interactions between trans-stilbene and G:C base pairs in the crystal structure of stilbene–diether (Sd)-capped DNAs 5′-GTTTTG-Sd-CAAAAC-3′., Adapted with permission from Egli, M.; Tereshko, V.; Murshudov, G. N.; Sanishvili, R.; Liu, X.; Lewis, F. D. Face-to-Face and Edge-to-Face π–π Interactions in a Synthetic DNA with a Stilbenediether Linker. J. Am. Chem. Soc. 2003, 125, 10842–10849. Copyright 2003 American Chemical Society.
Figure 15
Figure 15
Tivoli Gardens in Copenhagen, Denmark. https://www.tivoli.dk/en. Photo credit: “One Day in Copenhagen Itinerary” by Gina: https://www.onedayinacity.com/one-day-in-copenhagen/.

Similar articles

References

    1. Bob Letsinger, PhD–100 Years of History. Northwestern University, Department of Chemistry, Evanston, IL, 2021. Newsletter. https://chemistry.northwestern.edu/about/newsletter/2021-newsletters/fal....
    1. Caruthers M. H. Robert Letsinger: The Father of Synthetic DNA Chemistry. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 18098–18099. 10.1073/pnas.1420277111. - DOI - PMC - PubMed
    1. Egli M.; Manoharan M. Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics. Nucleic Acids Res. 2023, 51, 2529–2573. 10.1093/nar/gkad067. - DOI - PMC - PubMed
    1. Egli M.; Pallan P. S. Insights from Crystallographic Studies into the Structural and Pairing Properties of Nucleic Acid Analogs and Chemically Modified DNA and RNA Oligonucleotides. Annu. Rev. Biophys. Biomol. Struct. 2007, 36, 281–305. 10.1146/annurev.biophys.36.040306.132556. - DOI - PubMed
    1. Altmann K.-H.; Dean N. M.; Fabbro D.; Freier S. M.; Geiger T.; Häner R.; Hüsken D.; Martin P.; Monia B. P.; Müller M.; Natt F.; Nicklin P.; Phillips J.; Pieles U.; Sasmor H.; Moser H. E. Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals. Chimia 1996, 50, 168–176. 10.2533/chimia.1996.168. - DOI